Compare Nutanix Inc (NTNX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs Tango Therapeutics Inc. — how do they compare? Nutanix Inc trades at $69.68 (market cap $19.72B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Nutanix Inc is far larger — about 5.3× Tango Therapeutics Inc.'s market cap, and Nutanix Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nutanix Inc for 17 Days and Tango Therapeutics Inc. for 0 Days on average.
| NTNX | TNGX | |
|---|---|---|
Market Cap | $19.72B | $3.75B |
Volume | 2,236,075 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $74.63 | $32.90 |
52-Week Low | $34.41 | $7.50 |
Typical Hold Time | 17 Days | 0 Days |
Enterprise Value | $18.88B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $72.88, down 1.7% on the day but maintains strong technical momentum with bullish moving averages and positive analyst sentiment. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49, and impressive 86.8% gross margins. Recent Gartner Magic Quadrant recognitions highlight competitive strength in virtualization and container management platforms.
Outlook remains positive with 62.5% analyst buy ratings and $76.11 consensus price target, though elevated P/E of 14.1 and negative ROE of -395.76% warrant caution. Key risks include supply chain pressures and competitive IT services market, while AI growth initiatives and external storage expansion present upside potential.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
